Propofol is effective in chemotherapy-induced nausea and vomiting: A case report with quantitative analysis

Anesthesia and Analgesia

Volumn 89, Issue 3, 1999, Pages 798-799

  Tomioka, Shigemasa ^a   Kurio, Tomiko ^a   Takaishi, Kazumi ^a   Nakajo, Nobuyoshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; GRANISETRON; PROPOFOL; SEROTONIN AGONIST;

AGED; ARTERIAL OXYGEN SATURATION; ARTERIAL PRESSURE; ARTICLE; BREATHING RATE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG BLOOD LEVEL; HUMAN; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; NAUSEA; PRIORITY JOURNAL; TONGUE CARCINOMA; VOMITING;

AGED; ANESTHETICS, INTRAVENOUS; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; MALE; NAUSEA; PROPOFOL; TONGUE NEOPLASMS; VOMITING;

EID: 0032823050     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199909000-00051     Document Type: Article

References (15)

1. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-9.
2. Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-21.
3. Scher CS, Amar D, McDowall RH, Barst SM. Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients. Can J Anaesth 1992;39:170-2.
4. Borgeat A, Wilder-Smith OHG, Wilder-Smith CH, et al. Propofol improves patient comfort during cisplatin chemotherapy. Oncology 1993;50:456-9.
5. Borgeat A, Wilder-Smith O, Forni M, Suter PM. Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. Can J Anaesth 1994;41: 1117-9.
6. Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg 1987;66:1256-63.
7. Borgeat A, Wilder-Smith OHG, Saiah M, Rifat K. Subhypnotic doses of propofol possess direct antiemetic properties. Anesth Analg 1992;74:539-41.
8. Schulman SR, Rockett CB, Canada AT, Glass PSA. Long-term propofol infusion for refractory postoperative nausea: a case report with quantitative propofol analysis. Anesth Analg 1995; 80:636-7.
9. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-6.
10. Wilder-Smith OHG, Borgeat A, Chappuis P, et al. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993;72:2239-41.
11. Appadu BL, Lambert DG. Interaction of i.v. anaesthetic agents with 5-HT3 receptors. Br J Anaesth 1996;76:271-3.
12. Borgeat A. Subhypnotic doses of propofol do not possess anti-dopaminergic properties. Anesth Analg 1997;84:196-8.
13. Moyer JH. Effective antiemetic agents. Med Clin North Am 1957;41:405-32.
14. Appadu BL, Strange PG, Lambert DG. Does propofol interact with D2 dopamine receptor? Anesth Analg 1994;79:1191-2.
15. Tomioka S, Uchida D, Eguchi S, Nakajo N. Elimination of hypersensitive gagging reaction to dentistry by propofol at subhypnotic doses. Oral Dis 1998;4:279-80.